Emel Ficici
Emel Ficici has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Agustin Casimiro-Garcia
Pfizer Research & Development, Cambridge, MA, USA
2 shared publications Aliakbar Khalili Yazdi
Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada
2 shared publications- Cheryl H. Arrowsmith
Structural Genomics Consortium, Toronto, ON, Canada
2 shared publications - Dafydd R. Owen
Pfizer Research and Development, Cambridge, USA
2 shared publications - Dalia Barsyte-Lovejoy
Structural Genomics Consortium, Toronto, ON, Canada
2 shared publications Feng Wang
Pfizer Research & Development, Groton, CT, USA
2 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF20
Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors
Early-phase clinical trials of Bruton’s tyrosine kinase (BTK) degraders have demonstrated efficacy in patients with BTK inhibitor–resistant chronic lymphocytic leukemia (CLL). How clinical resistance to BTK degraders arises is unknown. In this study, we sequenced serial CLL samples from patients enrolled in phase I trials of zelebrudomide and bexobrutideg and observed recurrent expansion of preexisting BTKA428D mutations at relapse. Unlike previously studied BTK inhibitor resistance mutations, BTKA428D conferred pan-resistance to BTK inhibitors and degraders. In the absence of BTK-directed therapies, however, cells bearing BTKA428D exhibited a competitive disadvantage. A crystal structure of BTKA428D revealed that the mutant aspartate clashes with the adenine ring of adenosine triphosphate and the adenine-mimetic moiety of BTK inhibitors and degraders. Combining BTK degraders with venetoclax mitigated the expansion of BTKA428D. These results provide the molecular basis for clinical resistance to BTK degraders and will inform the development of next-generation BTK degrader therapies. Significance: BTK degraders are a promising new therapy for CLL. We demonstrate that BTKA428D is a recurrent BTK degrader resistance mutation in patients that confers pan-resistance to BTK inhibitors and degraders due to steric clash with their shared, adenine-mimetic moiety. Understanding this mutation can guide the development of next-generation BTK degraders.
- 30 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF20
Open AccessMolecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors
Early-phase clinical trials of Bruton’s tyrosine kinase (BTK) degraders have demonstrated efficacy in patients with BTK inhibitor–resistant chronic lymphocytic leukemia (CLL). How clinical resistance to BTK degraders arises is unknown. In this study, we sequenced serial CLL samples from patients enrolled in phase I trials of zelebrudomide and bexobrutideg and observed recurrent expansion of preexisting BTKA428D mutations at relapse. Unlike previously studied BTK inhibitor resistance mutations, BTKA428D conferred pan-resistance to BTK inhibitors and degraders. In the absence of BTK-directed therapies, however, cells bearing BTKA428D exhibited a competitive disadvantage. A crystal structure of BTKA428D revealed that the mutant aspartate clashes with the adenine ring of adenosine triphosphate and the adenine-mimetic moiety of BTK inhibitors and degraders. Combining BTK degraders with venetoclax mitigated the expansion of BTKA428D. These results provide the molecular basis for clinical resistance to BTK degraders and will inform the development of next-generation BTK degrader therapies. Significance: BTK degraders are a promising new therapy for CLL. We demonstrate that BTKA428D is a recurrent BTK degrader resistance mutation in patients that confers pan-resistance to BTK inhibitors and degraders due to steric clash with their shared, adenine-mimetic moiety. Understanding this mutation can guide the development of next-generation BTK degraders.
- 5 March 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 15 (3) , 1066-1071
Chemical tools for the Gid4 subunit of the human E3 ligase C-terminal to LisH (CTLH) degradation complex
A chemical probe (PFI-7) for the Gid4 subunit of the human E3 ligase CTLH degradation complex.
- 5 March 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 15 (3) , 1066-1071
Chemical tools for the Gid4 subunit of the human E3 ligase C-terminal to LisH (CTLH) degradation complex
A chemical probe (PFI-7) for the Gid4 subunit of the human E3 ligase CTLH degradation complex.
- Open Access
Chemical Tools for the Gid4 Subunit of the Human E3 Ligase C-terminal to LisH (CTLH) Degradation Complex
We have developed a novel chemical handle (PFI-E3H1) and a chemical probe (PFI-7) as ligands for the Gid4 subunit of the human E3 ligase CTLH degradation complex. Through an efficient initial hit-ID campaign, structure-based drug design (SBDD) and leveraging the sizeable Pfizer compound library, we identified a 500 nM ligand for this E3 ligase through file screening alone. Further exploration identified a vector that is tolerant to addition of a linker for future chimeric molecule design. The chemotype was subsequently optimized to sub-100 nM Gid4 binding affinity for a chemical probe. These novel tools, alongside the suitable negative control also identified, should enable the interrogation of this complex human E3 ligase macromolecular assembly.
Open AccessChemical Tools for the Gid4 Subunit of the Human E3 Ligase C-terminal to LisH (CTLH) Degradation Complex
We have developed a novel chemical handle (PFI-E3H1) and a chemical probe (PFI-7) as ligands for the Gid4 subunit of the human E3 ligase CTLH degradation complex. Through an efficient initial hit-ID campaign, structure-based drug design (SBDD) and leveraging the sizeable Pfizer compound library, we identified a 500 nM ligand for this E3 ligase through file screening alone. Further exploration identified a vector that is tolerant to addition of a linker for future chimeric molecule design. The chemotype was subsequently optimized to sub-100 nM Gid4 binding affinity for a chemical probe. These novel tools, alongside the suitable negative control also identified, should enable the interrogation of this complex human E3 ligase macromolecular assembly.
- Open Access
- 1 January 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100262
Conserved binding site in the N-lobe of prokaryotic MATE transporters suggests a role for Na+ in ion-coupled drug efflux
- 1 January 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100262
Open AccessConserved binding site in the N-lobe of prokaryotic MATE transporters suggests a role for Na+ in ion-coupled drug efflux
- Open Access
- 22 November 2017
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 149 (12) , 1149-1164
Asymmetry of inverted-topology repeats in the AE1 anion exchanger suggests an elevator-like mechanism
The membrane transporter anion exchanger 1 (AE1), or band 3, is a key component in the processes of carbon-dioxide transport in the blood and urinary acidification in the renal collecting duct. In both erythrocytes and the basolateral membrane of the collecting-duct α-intercalated cells, the role of AE1 is to catalyze a one-for-one exchange of chloride for bicarbonate. After decades of biochemical and functional studies, the structure of the transmembrane region of AE1, which catalyzes the anion-exchange reaction, has finally been determined. Each protomer of the AE1 dimer comprises two repeats with inverted transmembrane topologies, but the structures of these repeats differ. This asymmetry causes the putative substrate-binding site to be exposed only to the extracellular space, consistent with the expectation that anion exchange occurs via an alternating-access mechanism. Here, we hypothesize that the unknown, inward-facing conformation results from inversion of this asymmetry, and we propose a model of this state constructed using repeat-swap homology modeling. By comparing this inward-facing model with the outward-facing experimental structure, we predict that the mechanism of AE1 involves an elevator-like motion of the substrate-binding domain relative to the nearly stationary dimerization domain and to the membrane plane. This hypothesis is in qualitative agreement with a wide range of biochemical and functional data, which we review in detail, and suggests new avenues of experimentation.
- 22 November 2017
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 149 (12) , 1149-1164
Open AccessAsymmetry of inverted-topology repeats in the AE1 anion exchanger suggests an elevator-like mechanism
The membrane transporter anion exchanger 1 (AE1), or band 3, is a key component in the processes of carbon-dioxide transport in the blood and urinary acidification in the renal collecting duct. In both erythrocytes and the basolateral membrane of the collecting-duct α-intercalated cells, the role of AE1 is to catalyze a one-for-one exchange of chloride for bicarbonate. After decades of biochemical and functional studies, the structure of the transmembrane region of AE1, which catalyzes the anion-exchange reaction, has finally been determined. Each protomer of the AE1 dimer comprises two repeats with inverted transmembrane topologies, but the structures of these repeats differ. This asymmetry causes the putative substrate-binding site to be exposed only to the extracellular space, consistent with the expectation that anion exchange occurs via an alternating-access mechanism. Here, we hypothesize that the unknown, inward-facing conformation results from inversion of this asymmetry, and we propose a model of this state constructed using repeat-swap homology modeling. By comparing this inward-facing model with the outward-facing experimental structure, we predict that the mechanism of AE1 involves an elevator-like motion of the substrate-binding domain relative to the nearly stationary dimerization domain and to the membrane plane. This hypothesis is in qualitative agreement with a wide range of biochemical and functional data, which we review in detail, and suggests new avenues of experimentation.